MedPath

Self-Management Of Asthma By Forced Oscillation Technique

Not Applicable
Recruiting
Conditions
Asthma
Interventions
Other: Optimized self-management of asthma
Other: Conventional self-management of asthma
Registration Number
NCT04963140
Lead Sponsor
Restech Srl
Brief Summary

Self-management strategies for asthma, including patients engagement and adherence to personalised action plans with advice on recognizing and responding to deterioration in control with effective treatments can improve asthma outcomes and possibly reduce the risk of future exacerbations. However, the real-life evidence is that asthma control remains sub-optimal in the majority of cases, thus increasing the related socio-economic costs worldwide.

Because an increased variability of lung function remains a hallmark of poor asthma control and exacerbations, its assessment over time could contribute to the success of self-management plans. Previous studies have shown the potential of Forced Oscillation Technique (FOT) as a tool for monitoring increased variability of airway obstruction and for identifying the onset of acute deterioration of airway function.

The aim of this study is to test the hypothesis that a personalised self-management plan including FOT improves asthma control and reduces number of days with increased symptoms compared to conventional asthma treatment.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
200
Inclusion Criteria
  • Age: 6-65 years old

  • Diagnosis of persistent asthma

  • Treatment level at study entry:

    • For children 6-11 years: Step2 or Step3 of the GINA document
    • For adolescents and adults 12-65 years: Step2 under daily low-dose inhaled corticosteroids (ICS), Step 3 or Step 4 of the GINA document
  • Uncontrolled asthma (ACQ-5 > 1.5) that, according to the physician, does not warrant an immediate step-up of the treatment

  • History of moderate or severe exacerbations in the twelve (12) months prior to baseline visit

Exclusion Criteria
  • Use of oral, rectal or parenteral glucocorticosteroids 30 days before enrolment
  • Treatment with leukotriene receptor antagonist (LTRA)
  • Treatment with maintenance and reliever therapy (SMART/MART)
  • Smoking, current or previous with a history of 10 pack-years or more
  • Documented COPD or other concomitant clinically important diseases or cognitive impairment that, according to the physician, may interfere with the subject's ability or safety to participate in the study
  • Obesity (for subjects 6-19 years: BMI ≥ 95th percentile; for adults 20-65 years: BMI ≥ 40kg⋅m-2
  • For school-age children (6-11 years old): gestational age at birth < 37 weeks or documented bronchopulmonary dysplasia (BPD)
  • Prolonged absence from home during the monitoring period (i.e. at recruitment, expected ≥3 consecutive weeks for ≥2 times during the 9- month monitoring period) Subject currently enrolled in other clinical trials related or involving the study of the respiratory system
  • History of near-fatal asthma
  • Women who are pregnant, nursing or intending to become pregnant during the time of the study
  • Absence of health insurance coverage (applies to French centres only)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
InterventionOptimized self-management of asthmaIntervention subjects will monitor their lung function daily by Forced Oscillation Technique (FOT) device. The embedded algorithm signals when an increased risk of exacerbation is detected and subjects shall modify their treatment based on the action plan prescribed by the study doctor at enrolment and used for the self-management of their asthma
ControlConventional self-management of asthmaControl subjects will monitor their lung function daily by Forced Oscillation Technique (FOT) device. The embedded algorithm used in the intervention arm is disabled. Subjects will follow the action plan prescribed by the study doctor at enrolment for the self-management of their asthma
Primary Outcome Measures
NameTimeMethod
SymptomsFrom month no. 2 through study completion, an average of 7 months

Change of percentage of days with non-increased symptoms from baseline

Asthma Control6 months from enrolment

Change of percentage of subjects who improve their Asthma Control Questionnaire (ACQ-5)

Secondary Outcome Measures
NameTimeMethod
Day-to-day variability of respiratory resistanceThrough study completion, an average of 9 months

Change of average day-to-day coefficient of variation of inspiratory resistance (CVRinsp)

Accuracy of CVRinsp in detecting exacerbationsThrough study completion, an average of 9 months

In the control arm of the study only: accuracy, sensitivity and specificity of day-to-day variability of FOT parameters and of related prediction algorithm in identifying the occurrence of future moderate and severe exacerbations

Absence days from school/workThrough study completion, an average of 9 months

Change of absence days from work/school due to asthma

ExacerbationThrough study completion, an average of 9 months

Change of number of moderate and severe exacerbations

Asthma Control9 months from enrolment

Change of mean Asthma Control Questionnaire (ACQ-5); the expected ACQ-5 range is 0 - 3.5, with lower values indicating better asthma outcome

Controller medication usageFrom month no. 2 through study completion, an average of 7 months

Change of days with increased controller (inhaled corticosteroid (ICS) alone or in combination with long-acting bronchodilator (LABA))

Trial Locations

Locations (9)

Fondazione IRCCS Policlinico S. Matteo

🇮🇹

Pavia, Italy

ASST Papa Giovanni XXIII

🇮🇹

Bergamo, Italy

Istituto di Farmacologia Traslazionale (IFT) del CNR

🇮🇹

Palermo, Italy

Woolcock Institute of Medical Research

🇦🇺

Sydney, Australia

Grenoble University Hospital

🇫🇷

Grenoble, France

Azienda Unità Sanitaria Locale di Reggio Emilia

🇮🇹

Reggio Emilia, Italy

University Children's Hospital of Nancy

🇫🇷

Nancy, France

AOU Ospedali Riuniti Ancona

🇮🇹

Ancona, Italy

Azienda Ospedaliero, Universitaria Meyer

🇮🇹

Firenze, FI, Italy

© Copyright 2025. All Rights Reserved by MedPath